1. Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A, Colombo N, et al. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017; 28:iv72–iv83.
![crossref](/image/icon/bnr_ref_cross.gif)
2. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017; 3:524–548.
3. Zhu H, Luo H, Zhang W, Shen Z, Hu X, Zhu X. Molecular mechanisms of cisplatin resistance in cervical cancer. Drug Des Devel Ther. 2016; 10:1885–1895.
![crossref](/image/icon/bnr_ref_cross.gif)
4. Kartha RV, Subramanian S. Competing endogenous RNAs (ceRNAs): new entrants to the intricacies of gene regulation. Front Genet. 2014; 5:8.
![crossref](/image/icon/bnr_ref_cross.gif)
5. Fang Y, Fullwood MJ. Roles, functions, and mechanisms of long non-coding RNAs in cancer. Genomics Proteomics Bioinformatics. 2016; 14:42–54.
![crossref](/image/icon/bnr_ref_cross.gif)
6. Zhao Y, Sun H, Wang H. Long noncoding RNAs in DNA methylation: new players stepping into the old game. Cell Biosci. 2016; 6:45.
![crossref](/image/icon/bnr_ref_cross.gif)
7. O’Leary VB, Hain S, Maugg D, Smida J, Azimzadeh O, Tapio S, et al. Long non-coding RNA PARTICLE bridges histone and DNA methylation. Sci Rep. 2017; 7:1790.
![crossref](/image/icon/bnr_ref_cross.gif)
8. Han P, Chang CP. Long non-coding RNA and chromatin remodeling. RNA Biol. 2015; 12:1094–1098.
![crossref](/image/icon/bnr_ref_cross.gif)
9. Yoon JH, Abdelmohsen K, Gorospe M. Functional interactions among microRNAs and long noncoding RNAs. Semin Cell Dev Biol. 2014; 34:9–14.
![crossref](/image/icon/bnr_ref_cross.gif)
10. Schmitt AM, Chang HY. Long noncoding RNAs in cancer pathways. Cancer Cell. 2016; 29:452–463.
![crossref](/image/icon/bnr_ref_cross.gif)
11. Hirai I, Kimura W, Ozawa K, Kudo S, Suto K, Kuzu H, et al. Perineural invasion in pancreatic cancer. Pancreas. 2002; 24:15–25.
![crossref](/image/icon/bnr_ref_cross.gif)
12. Wang Y, Li Z, Zheng S, Zhou Y, Zhao L, Ye H, et al. Expression profile of long non-coding RNAs in pancreatic cancer and their clinical significance as biomarkers. Oncotarget. 2015; 6:35684–35698.
![crossref](/image/icon/bnr_ref_cross.gif)
13. Luan X, Wang Y. Long non-coding RNA XLOC_006390 promotes cervical cancer proliferation and metastasis through the regulation of SET domain containing 8. Oncol Rep. 2017; 38:159–166.
![crossref](/image/icon/bnr_ref_cross.gif)
14. Paraskevopoulou MD, Vlachos IS, Karagkouni D, Georgakilas G, Kanellos I, Vergoulis T, et al. DIANA-LncBase v2: indexing microRNA targets on non-coding transcripts. Nucleic Acids Res. 2016; 44:D231–D238.
![crossref](/image/icon/bnr_ref_cross.gif)
15. Yang D, Zhan M, Chen T, Chen W, Zhang Y, Xu S, et al. miR-125b-5p enhances chemotherapy sensitivity to cisplatin by down-regulating Bcl2 in gallbladder cancer. Sci Rep. 2017; 7:43109.
![crossref](/image/icon/bnr_ref_cross.gif)
16. Jia CW, Sun Y, Zhang TT, Lu ZH, Chen J. Effects of miR-125a-5p on cell proliferation, apoptosis and cell cycle of pancreatic cancer cells. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2016; 38:415–421.
17. Shen Z, Qin X, Yan M, Li R, Chen G, Zhang J, et al. Cancer-associated fibroblasts promote cancer cell growth through a miR-7-RASSF2-PAR-4 axis in the tumor microenvironment. Oncotarget. 2017; 8:1290–1303.
![crossref](/image/icon/bnr_ref_cross.gif)
18. Shi C, Xu X. MiR-670-5p induces cell proliferation in hepatocellular carcinoma by targeting PROX1. Biomed Pharmacother. 2016; 77:20–26.
![crossref](/image/icon/bnr_ref_cross.gif)
19. Chen X, Luo H, Li X, Tian X, Peng B, Liu S, et al. miR-331-3p functions as an oncogene by targeting ST7L in pancreatic cancer. Carcinogenesis. 2018; 39:1006–1015.
![crossref](/image/icon/bnr_ref_cross.gif)
20. Sun F, Yu M, Yu J, Liu Z, Zhou X, Liu Y, et al. miR-338-3p functions as a tumor suppressor in gastric cancer by targeting PTP1B. Cell Death Dis. 2018; 9:522.
![crossref](/image/icon/bnr_ref_cross.gif)
21. Zhao D, Sui Y, Zheng X. MiR-331-3p inhibits proliferation and promotes apoptosis by targeting HER2 through the PI3K/Akt and ERK1/2 pathways in colorectal cancer. Oncol Rep. 2016; 35:1075–1082.
![crossref](/image/icon/bnr_ref_cross.gif)
22. Epis MR, Giles KM, Barker A, Kendrick TS, Leedman PJ. miR-331-3p regulates ERBB-2 expression and androgen receptor signaling in prostate cancer. J Biol Chem. 2009; 284:24696–24704.
![crossref](/image/icon/bnr_ref_cross.gif)
23. Fujii T, Shimada K, Asano A, Tatsumi Y, Yamaguchi N, Yamazaki M, et al. MicroRNA-331-3p suppresses cervical cancer cell proliferation and E6/E7 expression by targeting NRP2. Int J Mol Sci. 2016; 17:1351.
![crossref](/image/icon/bnr_ref_cross.gif)
24. Epis MR, Giles KM, Beveridge DJ, Richardson KL, Candy PA, Stuart LM, et al. miR-331-3p and Aurora Kinase inhibitor II co-treatment suppresses prostate cancer tumorigenesis and progression. Oncotarget. 2017; 8:55116–55134.
![crossref](/image/icon/bnr_ref_cross.gif)
25. Cao Y, Zhang J, Xiong D, Wang D, Wu T, Huang A, et al. Hsa-miR-331-3p inhibits VHL expression by directly targeting its mRNA 3′-UTR in HCC cell lines. Acta Biochim Pol. 2015; 62:77–82.
![crossref](/image/icon/bnr_ref_cross.gif)
26. Chang RM, Yang H, Fang F, Xu JF, Yang LY. MicroRNA-331-3p promotes proliferation and metastasis of hepatocellular carcinoma by targeting PH domain and leucine-rich repeat protein phosphatase. Hepatology. 2014; 60:1251–1263.
![crossref](/image/icon/bnr_ref_cross.gif)
27. Cao Y, Chen J, Wang D, Peng H, Tan X, Xiong D, et al. Upregulated in hepatitis B virus-associated hepatocellular carcinoma cells, miR-331-3p promotes proliferation of hepatocellular carcinoma cells by targeting ING5. Oncotarget. 2015; 6:38093–38106.
![crossref](/image/icon/bnr_ref_cross.gif)
28. Guo X, Guo L, Ji J, Zhang J, Zhang J, Chen X, et al. miRNA-331-3p directly targets E2F1 and induces growth arrest in human gastric cancer. Biochem Biophys Res Commun. 2010; 398:1–6.
![crossref](/image/icon/bnr_ref_cross.gif)
29. Chen X, Pan M, Han L, Lu H, Hao X, Dong Q. miR-338-3p suppresses neuroblastoma proliferation, invasion and migration through targeting PREX2a. FEBS Lett. 2013; 587:3729–3737.
![crossref](/image/icon/bnr_ref_cross.gif)
30. Huang N, Wu Z, Lin L, Zhou M, Wang L, Ma H, et al. MiR-338-3p inhibits epithelial-mesenchymal transition in gastric cancer cells by targeting ZEB2 and MACC1/Met/Akt signaling. Oncotarget. 2015; 6:15222–15234.
![crossref](/image/icon/bnr_ref_cross.gif)
31. Fu X, Tan D, Hou Z, Hu Z, Liu G. miR-338-3p is down-regulated by hepatitis B virus X and inhibits cell proliferation by targeting the 3′-UTR region of CyclinD1. Int J Mol Sci. 2012; 13:8514–8539.
![crossref](/image/icon/bnr_ref_cross.gif)
32. Xu H, Zhao L, Fang Q, Sun J, Zhang S, Zhan C, et al. MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α. PLoS One. 2014; 9:e115565.
![crossref](/image/icon/bnr_ref_cross.gif)
33. Zhang P, Shao G, Lin X, Liu Y, Yang Z. MiR-338-3p inhibits the growth and invasion of non-small cell lung cancer cells by targeting IRS2. Am J Cancer Res. 2017; 7:53–63.
34. Chen JT, Yao KH, Hua L, Zhang LP, Wang CY, Zhang JJ. MiR-338-3p inhibits the proliferation and migration of gastric cancer cells by targeting ADAM17. Int J Clin Exp Pathol. 2015; 8:10922–10928.
35. Shang C, Hong Y, Guo Y, Xue YX. Mir-338-3p inhibits malignant biological behaviors of glioma cells by targeting MACC1 gene. Med Sci Monit. 2016; 22:710–716.
![crossref](/image/icon/bnr_ref_cross.gif)
36. Zhang Y, Shi B, Chen J, Hu L, Zhao C. MiR-338-3p targets pyruvate kinase M2 and affects cell proliferation and metabolism of ovarian cancer. Am J Transl Res. 2016; 8:3266–3273.
37. Han J, Li J, Tang K, Zhang H, Guo B, Hou N, et al. miR-338-3p confers 5-fluorouracil resistance in p53 mutant colon cancer cells by targeting the mammalian target of rapamycin. Exp Cell Res. 2017; 360:328–336.
![crossref](/image/icon/bnr_ref_cross.gif)
38. Liang Y, Xu X, Wang T, Li Y, You W, Fu J, et al. The EGFR/miR-338-3p/EYA2 axis controls breast tumor growth and lung metastasis. Cell Death Dis. 2017; 8:e2928.
![crossref](/image/icon/bnr_ref_cross.gif)
39. Sun NX, Ye C, Zhao Q, Zhang Q, Xu C, Wang SB, et al. Long noncoding RNA-EBIC promotes tumor cell invasion by binding to EZH2 and repressing E-cadherin in cervical cancer. PLoS One. 2014; 9:e100340.
![crossref](/image/icon/bnr_ref_cross.gif)
40. Jin X, Chen X, Hu Y, Ying F, Zou R, Lin F, et al. LncRNA-TCONS_00026907 is involved in the progression and prognosis of cervical cancer through inhibiting miR-143-5p. Cancer Med. 2017; 6:1409–1423.
![crossref](/image/icon/bnr_ref_cross.gif)
41. Frixa T, Donzelli S, Blandino G. Oncogenic microRNAs: key players in malignant transformation. Cancers (Basel). 2015; 7:2466–2485.
![crossref](/image/icon/bnr_ref_cross.gif)
42. Yang YK, Xi WY, Xi RX, Li JY, Li Q, Gao YE. MicroRNA-494 promotes cervical cancer proliferation through the regulation of PTEN. Oncol Rep. 2015; 33:2393–2401.
![crossref](/image/icon/bnr_ref_cross.gif)
43. Park S, Eom K, Kim J, Bang H, Wang HY, Ahn S, et al. MiR-9, miR-21, and miR-155 as potential biomarkers for HPV positive and negative cervical cancer. BMC Cancer. 2017; 17:658.
![crossref](/image/icon/bnr_ref_cross.gif)
44. Tang T, Wong HK, Gu W, Yu MY, To KF, Wang CC, et al. MicroRNA-182 plays an onco-miRNA role in cervical cancer. Gynecol Oncol. 2013; 129:199–208.
![crossref](/image/icon/bnr_ref_cross.gif)
45. Xie H, Lee L, Scicluna P, Kavak E, Larsson C, Sandberg R, et al. Novel functions and targets of miR-944 in human cervical cancer cells. Int J Cancer. 2015; 136:E230–E241.
46. Su K, Wang CF, Zhang Y, Cai YJ, Zhang YY, Zhao Q. miR-940 upregulation contributes to human cervical cancer progression through p27 and PTEN inhibition. Int J Oncol. 2017; 50:1211–1220.
![crossref](/image/icon/bnr_ref_cross.gif)
47. Hao Z, Yang J, Wang C, Li Y, Zhang Y, Dong X, et al. MicroRNA-7 inhibits metastasis and invasion through targeting focal adhesion kinase in cervical cancer. Int J Clin Exp Med. 2015; 8:480–487.
48. Gao YL, Zhao ZS, Zhang MY, Han LJ, Dong YJ, Xu B. Long noncoding RNA PVT1 facilitates cervical cancer progression via negative regulating of miR-424. Oncol Res. 2017; 25:1391–1398.
![crossref](/image/icon/bnr_ref_cross.gif)
49. Ma J, Fang B, Zeng F, Pang H, Zhang J, Shi Y, et al. Curcumin inhibits cell growth and invasion through up-regulation of miR-7 in pancreatic cancer cells. Toxicol Lett. 2014; 231:82–91.
![crossref](/image/icon/bnr_ref_cross.gif)